Nicholas Piramal

7/31/2019 Nicholas Piramal

http://slidepdf.com/reader/full/nicholas-piramal 1/24

PRESENTATION ON:

NICHOLAS PIRAMAL INDIA LTD

PRESENTED BY:

Arun Sharma



COMPANY PROFILE:

Nicholas Piramal India Limited (NPIL) is India's second largestPharmaceutical Healthcare company is a leader in the Cardio-vascular segment. It has a strong presence in Antibiotics and Respiratory segments,Pain management, Neuro-psychiatry and Anti-Diabetics segments. Thecompany is also making forays into Biotechnology in key therapeutic areasfor which it has formed several global alliances. For 2005-06, NPIL's

recorded a turnover of Rs 14.1 billion and profits after taxwereRs1.7billion.

NPIL's biggest brands in the pharma business are Phensedyl, Ismo,Supradyn, Gardenal, Stemetil, Haemaccel and Rejoint - these bring in 67 per cent of the business, while its secondary brands which include Paraxin,Flagyl and Omnatax contribute around 24 % of its revenues.

An aggressive player in the pharma industry, NPIL came into existence in1988 when it acquired Nicholas Laboratories from Sara Lee and in the last15 years grown to its leadership position through a series of well managed

acquisitions, mergers and alliances. Some of NPIL's major acquisitionsinclude the Indian operations of Roche Products Ltd., Boehringer MannheimIndia Ltd., Hoechst Marrion Roussel Ltd,'s Research Centre, Rhone PoulencIndia Ltd., ICI India Ltd.'s Pharma Division and Aventis' Researchfacilities.

NPIL has joint ventures and alliances with some of the finest global namesin the industry which include F. Hoffmann-La Roche Ltd., Switzerland;Allergan Inc., USA; UK; Gilead Sciences, USA; Cheissi, Italy; and IVAX

Corp; UK.

NPIL's core strengths are its 2700-strong field force that offers it the depthand width in the Indian market; successful brand building - today NPIL,together with its JVs, has 16 brands among the top 300 in the Indian PharmaIndustry; state-of-the-art manufacturing plants - NPIL's Hyderabad plant isthe only one in India to have USFDA approval for the entire facility, it is



also accredited and approved by MCA of UK, TGA of Australia and theEuropean and Canadian Drug Authorities, and its Pithampur plant in CentralIndia is accredited by reputed organizations like Allergan, Novartis, Solvayand IVAX, among others, which use it for toll manufacturing.

With the acquisition of Pfizer's Morepeth's manufacturing wite in UK, Nicholas Piramal through its wholly owned subsidiary NPILPharmaceuticals Limited, has emerged as one of the leading custommanufacturing organizations across the world.

Today, NPIL, is well poised to take advantage of the opportunities that willemerge in the bulk actives and intermediates market for contractmanufacturing at attractive price points of both on patent and off patentdrugs for the regulated markets of Europe, US and Japan. The company's

track record and credibility in respecting IPR is extremely good and isrespected globally. NPIL also has major investments in R&D which focuson formulations development, new chemical entity research, clinicalresearch from laboratories in India and abroad.

NPIL is the flagship company of the Rs. 2500 crore (US $ 500 million)Piramal Enterprises (PEL), one of India's largest diversified business houses.The Group is headed by Mr. Ajay Piramal, who is also the Chairman of

NPIL, and among the most respected names in Indian industry.



CORPORATE STUCTURE:

Management Team

Mr. Ajay G. Piramal, Chairman

Dr.(Mrs.) Swati Piramal, Director-Strategic Alliances & Communications

Mr. Pranzeet Singh, Director - (Formulations)

Dr. Somesh Sharma, Chief Scientific Officer

Mr. N. Santhanam, Executive Director & Chief Financial Officer

Mr. Ajay G. Piramal, Chairman,

Mr. Rajesh Khanna, Director

Mr. Y. H. Malegam, Director

Dr. Swati A. Piramal, Director - Strategic Alliances & Communication

Mr. S. Ramadorai, Director

Mr. Deepak Satwalekar, Director

Mr. R. A. Shah, Director

Mr. N. Vaghul, Director

Mr. Keki Dadiseth, Director

Mr. N. Santhanam, Executive Director & Chief Financial Officer

ASSOCIATE COMPANIES:

http://www.nicholaspiramal.com/aboutus_corstucture_mngteam1.htm























Joint Ventures, Alliances & Partnerships

NPIL is well positioned as a partner of choice for any multinationalcompany looking at the Indian market. It has an unmatched record of managing Joint Ventures/Alliances/Partnerships and a proven commitmentto IPR. Capabilities include strong brand management, sales andmarketing, a US FDA site-approved plant for on-and-off patent APIs andIntermediates, Basic Research, process innovation, Custom ChemicalSynthesis, Formulations R&D, NDDS, and a world-class ClinicalResearch Organisation.

Few Indian Pharmaceutical have as strong and consistent record insuccessfully and ethically managing JVs/Alliances and Partnerships as

NPIL has.

Its policy of respecting IPR and managing partnerships, in keeping with both the letter and the spirit of written agreements, has been widelyrespected and commended by its partners.

Today, NPIL has JVs/Alliances with some of the finest global names inthe Pharmaceutical and Healthcare industry. Its major current partnerships(including JVs/Alliances) are:

IN-LICENSING AGREEMENT:

Gilead Sciences, USA

Biogen Idec Inc

Genzyme Corporation



Laboratories Pierre Fabre

Ethypharm

Biosyntech Inc.

Cheisi, Italy

JV’S FOR INDIAN MARKETS

Allergan Inc., USA

Boots Plc., UK

MISSION:

Making a difference to the Quality of Life by reducing the burden of disease.



VISION:

• To become the most admired pharmaceutical company in India withleadership in market share, research and profits by:

•

Building distinctive sales and marketing capabilities

• Inculcating a high performance culture

• Being the partner of choice

• Always adhering to ‘our values’ based on our obligations as trusteesof customers, employees, shareholders and society

• We shall pursue world-class standards in our People, Products,Processes, Partnerships and Performance

• Encouraging Innovation and Nurturing Intellectual Capital

CORPORATE STRATEGY:

NPIL's medium-term business model envisages achieving leadership in thedomestic pharmaceuticals market, and building a strong de-riskedinternational business around the company’s core strengths inmanufacturing, marketing and R&D. s



NPIL has some of the strongest brands in India and a demonstrated ability to build brands and leadership through markets characterized by intensecompetition. The company's strategy of leveraging its competencies, builtassiduously over the years through a growing domestic market, andaddressing manufacturing opportunities in the developed global

pharmaceutical markets sharply defines their strategic intent.

The Indian domestic market is significant since it represents the base onwhich NPIL is building a global business model. India represents a sixth of humanity. Although buying power and pharmaceuticals penetration iscurrently lower than some of the more developed markets, it is expected togrow to US $ 25 billion by the year 2010.

Nicholas Piramal India Limited has an unmatched record of managing JointVentures/Alliances/Partnerships and a proven commitment to IPR.Capabilities include sales & marketing, a US FDA site-approved plant for on-and-off patent APIs and Intermediates, Basic Research, process

innovation, Custom Chemical Synthesis, Formulations R&D, NDDS, and aworld-class Clinical Research Organisation.



SECTOR SYNOPSIS:

The Indian pharmaceutical industry is a success story providing employment

for millions and ensuring that essential drugs at affordable prices are

available to the vast population of this sub-continent.”

---- Richard Gerster.

The Indian Pharmaceutical Industry today is in the front rank of India’sscience-based industries with wide ranging capabilities in the complex fieldof drug manufacture and technology. A highly organized sector, the Indian



Pharma Industry is estimated to be worth $ 4.5 billion, growing at about 8 to9 percent annually. It ranks very high in the third world, in terms of technology, quality and range of medicines manufactured. From simpleheadache pills to sophisticated antibiotics and complex cardiac compounds,almost every type of medicine is now made indigenously.

Playing a key role in promoting and sustaining development in the vital fieldof medicines, Indian Pharma Industry boasts of quality producers andmany units approved by regulatory authorities in USA and UK. Internationalcompanies associated with this sector have stimulated, assisted andspearheaded this dynamic development in the past 53 years and helped to

put India on the pharmaceutical map of the world.

The Indian Pharmaceutical sector is highly fragmented with more than

20,000 registered units. It has expanded drastically in the last two decades.The leading 250 pharmaceutical companies control 70% of the market withmarket leader holding nearly 7% of the market share. It is an extremelyfragmented market with severe price competition and government pricecontrol.

The pharmaceutical industry in India meets around 70% of the country'sdemand for bulk drugs, drug intermediates, pharmaceutical formulations,chemicals, tablets, capsules, orals and injectibles. There are about 250 largeunits and about 8000 Small Scale Units, which form the core of the

pharmaceutical industry in India (including 5 Central Public Sector Units).These units produce the complete range of pharmaceutical formulations, i.e.,medicines ready for consumption by patients and about 350 bulk drugs, i.e.,chemicals having therapeutic value and used for production of

pharmaceutical formulations.

Following the de-licensing of the pharmaceutical industry, industriallicensing for most of the drugs and pharmaceutical products has been doneaway with. Manufacturers are free to produce any drug duly approved by the

Drug Control Authority. Technologically strong and totally self-reliant, the pharmaceutical industry in India has low costs of production, low R&Dcosts, innovative scientific manpower, strength of national laboratories andan increasing balance of trade. The Pharmaceutical Industry, with its richscientific talents and research capabilities, supported by Intellectual PropertyProtection regime is well set to take on the international market.



ADVANTAGE INDIA

Competent workforce: India has a pool of personnel with high managerial

and technical competence as also skilled workforce. It has an educated work force and English is commonly used. Professional services are easilyavailable.

Cost-effective chemical synthesis: Its track record of development, particularly in the area of improved cost-beneficial chemical synthesis for various drug molecules is excellent. It provides a wide variety of bulk drugsand exports sophisticated bulk drugs.

Legal & Financial Framework: India has a 53 year old democracy and

hence has a solid legal framework and strong financial markets. There isalready an established international industry and business community.

Information & Technology: It has a good network of world-classeducational institutions and established strengths in InformationTechnology.

Globalization: The country is committed to a free market economy andglobalization. Above all, it has a 70 million middle class market, which is

continuously growing.

Consolidation: For the first time in many years, the international pharmaceutical industry is finding great opportunities in India. The processof consolidation, which has become a generalized phenomenon in the world

pharmaceutical industry, has started taking place in India.

THE GROWTH SCENARIO

India's US$ 3.1 billion pharmaceutical industry is growing at the rate of 14 percent per year. It is one of the largest and most advanced among thedeveloping countries.

Over 20,000 registered pharmaceutical manufacturers exist in the country.The domestic pharmaceuticals industry output has exceeded Rs260 billion inthe financial year 2002, which accounts for merely 1.3% of the global



pharmaceutical sector. Of this, bulk drugs account for Rs 54 bn (21%) andformulations, the remaining Rs 210 bn (79%). In financial year 2001,imports were Rs 20 bn while exports were Rs87 bn.

STEPS TO STRENGTHEN THE INDUSTRY

Indian companies need to attain the right product-mix for sustained futuregrowth. Core competencies will play an important role in determining thefuture of many Indian pharmaceutical companies in the post product-patentregime after 2005. Indian companies, in an effort to consolidate their

position, will have to increasingly look at merger and acquisition options of either companies or products. This would help them to offset loss of new

product options, improve their R&D efforts and improve distribution to penetrate markets.

Research and development has always taken the back seat amongst Indian pharmaceutical companies. In order to stay competitive in the future, Indiancompanies will have to refocus and invest heavily in R&D.

The future of the industry will be determined by how well it markets its products to several regions and distributes risks, its forward and backwardintegration capabilities, its R&D, its consolidation through mergers andacquisitions, co-marketing and licensing agreements.

COMPETITORS

DR.REDDY’S

Dr. Reddy's Laboratories is a global, vertically integrated company with a presence across the pharmaceutical value chain, producing and deliveringsafe, innovative, and high quality finished dosage forms, active

pharmaceutical ingredients and biotechnology products, which are marketedto over 100 countries including US, Europe, Russia, Asia Pacific, India and



China. The company is dedicated to bring affordable healthcare to peopleacross the world, regardless of geographic and socio-economic barriers.

The Company conducts NCE drug discovery research in the areas of diabetes, cardiovascular, anti-infectives, inflammation and cancer. Its drugdiscovery effort is carried out at its research facilities in Atlanta, USA, andin Hyderabad, India.

Corporate Headquaters:

Hyderabad, India

Research Facilities In:

Atlanta, USA & Hyderabad, India

Manufacturing Facilities In:

6 Facilities of Active Pharmaceutical ingredients in AP, India2 Technology Development Centres for Custom Pharmaceutical Services(CPS) in India and I facility of CPS in Cuvernavaca, Mexico.6 Finished Dosage Units in India.1 Biologics facility in India

People:

Employees: over 8500Sales Staff: over 1,700 worldwideScientists: more than 850 of whom over 200 are dedicated to drug discovery.

Financials:

Net Revenues for fiscal year 2006 at US $546 million. Net income for fiscal year 2006 at $37 million.

RANBAXY



Ranbaxy Laboratories Limited, India's largest pharmaceutical company, isan integrated, research based, international pharmaceutical company,

producing a wide range of quality, affordable generic medicines, trusted byhealthcare professionals and patients across geographies. The Company isranked amongst the top ten global generic companies and has a presence in23 of the top 25 pharma markets of the world. The Company with a globalfootprint in 49 countries, world-class manufacturing facilities in 11 and adiverse product portfolio, is rapidly moving towards global leadership,riding on its success in the world’s emerging and developed markets.

Ranbaxy is one of the leading pharma Companies in India commanding amarket share of 5.07%. (Source : ORG-IMS, March, 2007). The Companyhas clocked sales of USD 286 Mn (2006) registering a growth of over 17%.Growing ahead of the market the Company has enhanced its competitive

position in the domestic market through its focused approach. TheCompany’s business has been realigned to its customer groups andinvestments have been made in high growth segments. These efforts haveresulted in strengthening its Chronic franchise (Life Style led) as well as hasreinforced its leading position in the Acute segment.

In the NDDS segment, Ranbaxy is the market leader with 7.9% market shareand its NDDS product portfolio contributes to about 9% of its total turnover.Its product portfolio spans across Acute & Chronic Business covering Anti-infectives, Nutritionals, Gastro-intestinals, Pain Management ( Acute)

Cardiovasculars, Dermatologicals, Central Nervous Systems(Chronic)segments.

Company’s India operations are a dominant force in a number of participating therapeutic segments, for example Anti-infectives, Statins,Dermatology and Pain Management Operations are structured into 9Strategic Business Units. A publicly listed company, Ranbaxy India is also amember of IPA (Indian Pharmaceutical Alliance) & OPPI (Organization of Pharmaceutical Producers of India).

Amongst the pharmaceutical companies in India, Ranbaxy has the largestR&D budget with an R&D spend of over US $ 100Mn

Ranbaxy views its R&D capabilities as a vital component of its businessstrategy that will provide the company with a sustainable, long-term



competitive advantage. The company today has a pool of 1,200 scientistswho are engaged in path-breaking research.

The robust R&D environment within the company for both drug discovery& development and for generics is designed to bring into sharper focus, theunique needs of both equally. Ranbaxy's endeavour is to be a leader in thegenerics space and also to build a strong proprietary prescriptions business

based on the Company's NDDS and NCE (New Chemical Entity) researchoutcomes.

Key Strengths

• Leadership in Novel Drug Delivery System (NDDS) products, whichoffer value-added differentiation over conventional products. Key

brands include Cifran OD (Ciprofloxacin), Zanocin OD (Ofloxacin)& Sporidex AF (Cephalexin)

• Strong brand building capabilities, reflected in the fact that 20 brands feature in the “Top-300 brands of the Industry” list. Theleading 5 brands are Sporidex (Cephalexin), Cifran (Ciprofloxacin),Mox (Amoxycillin), Zanocin (Ofloxacin) & Volini (Diclofenac)

• A well-built customer interface, with one of the highest customer coverage across India, and an excellent franchise with bothGeneralists & Specialists. This is proven by Ranbaxy India’sCorporate Image being perceived as ‘Best-in-Class’ by customers

(source: AC Nielsen ORG MARG Report, June 2004)• Great emphasis is placed on Knowledge Management and Medico-

marketing initiatives such as Advisory Board Meetings, PostMarketing Surveillance Studies and Continuous Medical Education

programs. These have resulted in an excellent customer relationshipwith the medical fraternity. More than 2000 interface programs(Symposia, CME’s) are conducted and about 20 Clinical Papers

published annually

• With a futuristic approach, the India operations attempts to capitalize

on the fast- emerging, high-growth segments with innovative productsand services:

• Biological formulations such as Verorab (Rabies Vaccine) andVaxigrip (Flu Vaccine), which require competencies to propagate thenewer concepts in the market place. These products are being in-licensed or taken on Co-promotion from Sanofi Pastuer



• High end anti-infectives such as Cilanem (Imipenem+Cilastatin) &Faronem (Faropenem) have been launched for the first time in

India. Ranbaxy is championing the concept of Penems/Carbapenmens , locally

• Dry Power & Metered Dose Inhalers have been launched in theRespiratory segment. All Metered Dose Inhalers are HFA based

formulations, environment friendly inhalers. It is for the first time inIndia, that a company has launched its entire HFA propellant basedMDI range. The world’s first novel product, Osovair (Formoterol +Ciclesonide) inhalation capsules has been introduced in the Indianmarket.

• Anti-diabetic franchise has been further consolidated with launch

of Insucare (Insulin) with an innovative delivery mechanism -“Controlled Insulin Logistics” This ensures that the cold chain, vital

for product efficacy, is maintained.• A slew of products have been launched in the Dermatology segment:

Suncross (Sunscreen lotion), Sotret (Isotretnoin), Eflora (Eflornithine)

CIPLA

Cipla is 2nd largest pharmaceutical company in India in terms of retail sales.Cipla manufactures an extensive range of pharmaceutical & personal care

products and has presence in over 170 countries across the world. Cipla's product range includes Pharmaceuticals, Animal Health Care Products,OTC, Bulk Drugs, Flavours & Fragrances, and Agrochemicals. Cipla also

provides a host of consulting services such as preparation of productsmaterial specifications, evaluation of existing production facilities to meetGMP, definition of appropriate plant size and technologies etc

Exports for the financial year ended March 31, 2007 amounted to

more than Rs. 17,800 million. Cipla exports raw materials,intermediates, prescription drugs, OTC products and veterinary

products . Cipla also offers technology for products and processes. Technical know-how/fees received during the year 2006-07 amounted to Rs. 764.70 million. Cipla's manufacturingfacilities have been approved by the following regulatoryauthorities:



Food and Drug Administration (FDA), USA.Medicines and Healthcare products Regulatory Agency (MHRA),UK.Therapeutic Goods Administration (TGA), Australia.Medicines Control Council (MCC), South Africa.

National Insti tute of Pharmacy (NIP), Hungary.Pharamaceutical Inspection Convention (PIC), Germany.World Health Organisation (WHO) Department of Health, Canada.State Institute for the Control of Drugs, Slovak Republic ANVISA,Brazil.

Cipla products are bought by over 170 countries located in the followingregions:



MANUFACTURING:

NPIL's Hyderabad-based plant is one of the very few USFDA site-approved plants in India, is capable of all types of reactions. The plant isunique in that it has USFDA approval for the entire facility and notmerely a product line, without and deficiency or non-conformity i.e.without any 483s. It is also accredited and approved by MCA of UK,TGA of Australia and the European and Canadian Drug Authorities.

The company's state-of-the-art plant at Pithampur in Central India isreckoned among the finest in this part of the world. Accredited byreputed organizations, the plant also does toll manufacturing for reputed

MNCs like Allergan, Novartis, Solvay and IVAX, in addition to a host of leading Indian companies.

The state-of-the-art domestic formulations plant, built at a cost of Rs1.6bn.was commissioned in 2006 in a record twelve months.

NPIL has in place all the key capabilities critical to this business -manufacturing, process development (integrating with R&D), IPR

protection, BD and supply chain management.

Significantly, NPIL is also well placed to offer manufacturing servicesacross the entire life cycle of a product, including the development stage.Their capabilities today include not just lower cost dosage manufacturing,

but the ability to manage costs through process innovation and the skills toaid in formulations R&D development and New Drug Delivery Systems.



PRODUCT RANGE:

• Analgesic/Anti-inflammatory

• Antibiotics

• Antihistamines• Cardiovascular

• Central Nervous System

• Diabetes

• Dermatology

• Endocrinology

• Gastroenterology

• Multivitamins/Nutraceuticals

• Critical Care

• Pulmonary/Respiratory• Trauma/Emergency

BRANDS, SALES & MARKETING:

NPIL can leverage opportunities and manage all challenges that could arisein the domestic Indian market. The restructuring of their product portfoliointo primary, secondary and tertiary brands in 2001-02 has helped create

power brands that are now growing above industry growth rates. New products have a sharper focus with a specialized management team lookinginto opportunities and launches. In the last 2 years, NPIL has grown marketshare through a combination of new products, innovative selling and brandmanagement.



In-licensing and Alliances remain an important component of their strategyfor the near to medium term. Given its importance in their strategy, thecompany has a dedicated management team to source new product and

alliances opportunities, both domestically and globally.

With a field force of about 3,000, our sales, marketing and distributionnetwork is among the largest in the country. The field forces are IT enabledand segregated into discrete divisions with a disease focus to improvecustomer coverage. The size of the field forces and the strong training andmotivation inputs that are continually provided have enabled the companyleverage scale and penetration significantly. This can be seen from the factthat despite severe competition across the market, the company has

maintained its Prescription trend and price lines across key segments.

DOMESTIC MARKETING & SALES

The size of NPIL's field forces

and the strong training and

motivation inputs that are

continually provided have

enabled the company leverage

scale and penetrationsignificantly.



NPIL has strong brand and brand life-cycle management systems designedto derive competitive advantages in one of the most challenging

pharmaceutical markets in the world. The company has one of the widest product portfolios in India, spanning nine key therapeutic areas, includingCardio-vascular, Neuro-psychiatry, Oncology, Diabetes Management,Respiratory, Anti-infectives, Gastro-intestinals, Dermatology and NSAIDS.The company has alliances across the globe in key therapeutic areas.

With a sharp the focus on disease areas, the company has specialist fieldforces that cover more than 75% of all key doctor segments. Each highgrowth area like Cardiovascular, Diabetes, Central Nervous System,Gynaecology, Dermatology, and Oncology have a dedicated field force thatis highly trained. The multi-specialty approach to mass consumption brands

and products, which require considerable reach and penetration across thecountry, enabled NPIL to derive considerable advantages from skill, scaleand size.

The company’s field force has implemented best-in-class practices,including knowledge management support for doctors. The field forces arealso IT enabled to improve customer servicing capabilities. CRMinvestments in the field force is augmented considerably every year. Theywill invest in augmenting our field force to strengthen doctor coverage andsharpen our divisional focus.

The size of the field forces and the strong training and motivation inputs thatare continually provided have enabled the company leverage scale and

penetration significantly. This can be seen from the fact that despite severecompetition across the market, the company has maintained its prescriptiontrend and prices across key segments.

FORMULATIONS PACKAGING AND DISTRIBUTION:



NPIL Pharma's Morpeth site carries out packaging for over 300 SKUs androutinely supplies products to over 100 markets including US, Europe andJapan.

The site has a wide range of packaging equipment

Modern packaging facility with individual booths for blister packaginglines

• Six off fully integrated blister packaging lines• Output speed up to 450 blisters per min & 300 packs per min• Both cold form and laminate capabilities• Capability to pack multiple actives on same blister strip• Modern and sophisticated ‘defect’ detection and rejectionsystems on all lines•

Bottle filling and packaging capability• Area available for hand packaging to accommodate ‘special’

presentation.

Warehousing and Distribution facilities :

cGMP warehouse with up to 7000 pallet locationsLow temperature storage area separately available• All stock transfers controlled by validated computerized stock control system

• Own Artwork development and generation teams

PRESENT STATUS:



Nicholas Piramal India Limited is one of India's largest companies with anunmatched record of managing JVs/Alliances/Partnerships, and a provencommitment to IPR. With strong brand management and sales capabilities, aUS FDA site-approved plant for on-and-off patent APIs and Intermediates,Basic Research, Process Innovation, Custom Chemical Synthesis,Formulations R&D, NDDS, and a world-class, accredited Clinical ResearchOrganization, NPIL is poised to emerge as India's pharma powerhouse.

With growth fuelled through a strategy of partnerships, quality acquisitions, brand building,focused selling and manufacturing, NPIL'sconsolidated net sales turnover was US$ 313 million(INR 14.1 billion) in 2005-06 (April to March)".

NPIL has emerged among the leaders in Indian pharma with a unique mix of inorganic and organicgrowth fuelled through a strategy of acquisitions,

brand building and focused selling, andmanufacturing. The company has one of the widest

product portfolios in India, spanning nine keytherapeutic areas, including the Cardio-vascular, Euro-psychiatry, Oncology,Diabetes Management, Respiratory, Anti-infectives, Gastro-intestinals,Dermatology.

The company has followed a multi-pronged strategy to integrate andmaximize synergies with the planned acquisitions and develop andconsolidate its major strength in marketing to therapeutic niches.

Managed by a team of highly proficient industry professionals, NPIL's keystrengths come from its strong brand building, selling and distribution,manufacturing and alliance/partnership management skills. The last,especially, are quite unique in the Indian context - few IndianPharmaceutical have exhibited such a strong and consistent record in

successfully and ethically managing JVs/Alliances and Partnerships as NPILhas.

Its policy of respecting IPR and managing partnerships, in keeping with boththe letter and the spirit of written agreements, has been widely respected andcommended by its partners.



NPIL is the flagship company of the Rs. 2500 crore (US $ 550 million)Piramal Enterprises (PEL), one of India's largest diversified business houses.

Nicholas Piramal

Documents

Transcript of Nicholas Piramal